Lavender Sky Health review: upfront costs and refill rules

Lavender Sky Health is worth comparing if you want to pay for care and orders as needed. Its FAQ says it does not automatically rebill you. That flexibility does not make a prepaid medication order refundable.

This review focuses on purchasing decisions, not treatment outcomes. We checked public pages on September 14, 2026. We did not complete signup, pay for treatment, test delivery or support, or independently verify clinician and pharmacy credentials. There was no independent human or clinical review of this revision. The calculations below are ours; service promises are attributed to the provider.

What you would need to pay

The consultation page lists $65 for a new patient and $40 for a follow-up. Medication is separate. The fee pays for an evaluation, not a guaranteed prescription.

Selected examples from the treatment catalog, not an exhaustive price list:

Last column = order + $65. These are calculated starting budgets, not observed checkout quotes. The catalog lists medication, shipping and supplies as included. Eligibility, prescribed dose and pharmacy availability determine the actual order.

Compare the same length of time

A $195 supply lasting eight weeks costs $24.38 per week; at ten weeks it costs $19.50. That is $97.50 or $78 per 4-week period before consultation. Including the first consult gives $130 or $104 per four weeks.

This arithmetic explains why a low equivalent is not the amount you can pay today. It also depends on the supply actually lasting that long. A four-week period is 28 days, not a calendar month. Do not stretch doses or vial use to reach the cheaper figure.

For the Hallandale Tier 1 example, the initial $314 spreads to $157 per four weeks over eight weeks, or $125.60 over ten. These scenarios compare budgets, not equivalent treatments or recommended doses.

The first refill can add another consultation

The pre-patient guide says patients starting a custom GLP-1 for the first time need a follow-up before your first refill. Patients transferring with documentation may be treated differently. Do not assume the initial consult covers every order for six months.

For planning, add the $40 follow-up when required; the next medication invoice depends on the approved plan. Lavender Sky’s FAQ says eligible refills between required consultations carry no separate consult or provider fee.

The service-pricing page describes routine follow-ups every six months during active treatment and every twelve months on maintenance, with earlier visits in some circumstances. Your provider sets your actual schedule.

Check your state before comparing pharmacies

The pharmacy coverage page lists Hyalo/New Life Rx, OptioRx, Red Rock and Strive for California. It does not list ReviveRx, Hallandale or Southend there.

That means the examples above should not be treated as California offers. Start with pharmacies listed for your state, then compare their eligible plans. A nationwide provider directory label does not establish that a particular pharmacy or formulation can serve you. This is a check of Lavender Sky’s published list, not an independent licensing audit.

Stopping treatment and getting a refund are different

According to Lavender Sky’s terms, medication orders become final when submitted to the pharmacy. Processing can start immediately after payment. Stopping future orders does not undo an order already in progress.

The policies need careful reading: the billing section says electronic consultations are non-refundable once submitted, even before review; the appointment section describes pre-consult cancellation refunds minus a 5% processing fee. Do not assume the appointment refund wording applies to an e-consult. Ask support to confirm your specific consult’s terms before paying.

Our practical recommendation: resolve pharmacy, formulation and invoice questions first. Paying while expecting to sort them out afterward risks a non-refundable charge.

What makes this useful, and where it falls short

The published catalog lets you compare pharmacy-specific orders without relying on a single headline price. The downside is that you must reconcile supply length, consultation timing and state coverage yourself.

Brand-name plans require a separate check: the treatment catalog lists a $25 monthly service fee excluding medication. The broad “no memberships” language should not be read as “no ongoing service cost.” Confirm how that fee is invoiced and obtain the medication price from the dispensing pharmacy.

A longer list of formulations is not evidence of better care. We have not established superior outcomes from added vitamins, amino acids or a particular delivery format. FDA guidance says compounded drugs are not FDA-approved and should be used only when a patient’s medical needs cannot be met by an approved drug. A clinician should determine suitability.

FDA also recommends discarding multi-dose sterile vials within 28 days after first use, even if compounder instructions allow longer. Ask how many vials an extended order contains and whether the usable supply supports the quoted duration. A package’s advertised weeks are not independent evidence of safe use after opening.

Before paying

Get these answers in writing:

• Which pharmacy and exact formulation would fill the prescription in my state?
• What is the full invoice, including consultation and any service fee?
• How many vials arrive, and what are their unopened and after-opening limits?
• Will my next order require the $40 follow-up?
• When does my particular consultation or medication payment become non-refundable?

These are unresolved patient-specific checks, not claims that we tested the answers.

Compare Mochi’s recurring costs and Gimme Care’s subscription commitments, or use our provider directory to build a shortlist. Compare total cash due and usable supply on the same basis; a cheaper advertised equivalent alone does not establish the better option.

Check Lavender Sky’s current plans

Correction history

September 14, 2026: replaced unsupported pharmacy-superiority and additive-benefit claims, removed an overstated alternative-provider endorsement and an unsupported review score, and added upfront calculations, refill restrictions, state limitations and refund-policy distinctions. The original March 8 publication date is unchanged.